Skip to main content
Premium Trial:

Request an Annual Quote

NIH Grants HelixBind $3M for Early Detection Lyme Test

NEW YORK – Infectious disease diagnostic company HelixBind announced Thursday it has received $3 million from the National Institutes of Health to evaluate the company's early detection test for Lyme disease. 

The money is to support clinical studies evaluating the test, which detects DNA from tick-borne bacteria Borrelia burgdorferi directly from the patient's blood. The test has a limit of detection of less than 1 cell per milliliter and can detect the infection at "the earliest timepoint," the company said in a statement.

HelixBind CEO Alon Singer said diagnosis of Lyme disease is currently limited by the sensitivity of existing tests, so "this new grant from the NIH will help us demonstrate whether the improved sensitivity of our test can improve diagnosis." 

The firm has clinical studies planned for 2021's tick season and is looking to add additional clinical partners, it said.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.